Risultati per: Malattia Arteriosa Periferica (PAD) - Indicazioni su diagnosi e gestione

Alcune sono causa di sordocecità,fondamentale intervento precoce

Alcune sono causa di sordocecità,fondamentale intervento precoce

Epidemia iniziata il 21 gennaio dopo che 3 bambini hanno mangiato un pipistrello

Airo: “Radioterapia è speranza, serve integrazione specialisti”

In Italia oltre 100mila con patologie rare non diagnosticate

Nel 2024: +10% di ingressi. Il plauso sindaco di Loreto, Pieroni

In Italia 3500 casi anno fase avanzata,anche 6 mesi per diagnosi

Cruciale per questa neoplasia gravata dalla diagnosi tardiva

Psichiatri e oncologi: ‘Da Balti a Fedez, messaggio di coraggio’

Psichiatri e oncologi: ‘Da Balti a Fedez, messaggio di coraggio’

Vaccino offerto a chi è a rischio per comportamenti o condizioni

Per circa il 60% degli studenti delle scuole superiori di Milano che hanno partecipato all’incontro ‘Dal Laboratorio alla vita’

Introduction
The infrapatellar fat pad and synovium are the sites of immune cell infiltration and the origin of proinflammation. Studies have shown that Hoffa’s synovitis may be a sign of early-stage osteoarthritis (OA). However, there have been no effective interventions specifically for Hoffa’s synovitis.

Methods and analysis
We will conduct a multicentre, multi-blind (participant, physician, outcome assessor and data analyst blinded) randomised controlled trial to compare the effectiveness of an intra-infrapatellar fat glucocorticoid versus an intra-articular injection for Hoffa’s synovitis in patients with knee OA. We will recruit 236 knee OA patients with Hoffa’s synovitis at outpatient clinics in three centres. We will randomly allocate them to two groups in a 1:1 ratio. One group will receive ultrasound-guided injection of 40 mg (1 mL) triamcinolone acetonide into the infrapatellar fat pad; the other group will receive ultrasound-guided injection of 40 mg (1 mL) triamcinolone acetonide into the knee joint cavity. All patients will be followed up at 2, 4, 8, 12 and 24 weeks after the injection. Primary outcomes are (1) Hoffa’s synovitis improvement rate, measured with the MRI Osteoarthritis Knee Score system (superiority outcome) at 24 weeks and (2) pain intensity, measured with the Western Ontario and McMasters University Osteoarthritis Index (WOMAC) at 2 weeks post-injection. Secondary outcomes include Hoffa’s synovitis score at 2 weeks post-injection, pain intensity with the numerical rating scale, WOMAC questionnaire score improvements (function, joint stiffness and total score), improvement rates in effusion synovitis at 2 and 24 weeks, articular cartilage thickness changes at 2 and 24 weeks, Intermittent and Constant Osteoarthritis Pain score, quality of life measured with the EuroQol-5D, OARSI-OMERACT response indicators, co-interventions and side effects at 2, 4, 8, 12 and 24 weeks.

Ethics and dissemination
Ethical approval has been granted by the Medical Ethics Committee of the Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (2023–178). Written informed consent will be obtained from all patients prior to data collection. The findings of this research will be shared through presentations at academic conferences and publications in peer-reviewed journals.

Trial registration number
ChiCTR2400080474.